Advertisement
Advertisement
CAMP
CAMP4 Therapeutics Corporation Common Stock
4.50
USDSponsored
0.00
0.00%
May 13, 15:59 UTC -4
Closed
Pre-Market
4.50
0.00
+0.11%
CAMP Earnings Reports
Positive Surprise Ratio
CAMP beat 2 of 7 last estimates.
29%
Next Report
Date of Next Report
Aug 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
$1.24M
/-$0.21
Implied change from Q1 26 (Revenue/ EPS)
-3.83%
/-34.38%
Implied change from Q2 25 (Revenue/ EPS)
-16.87%
/-66.13%
CAMP4 Therapeutics Corporation Common Stock earnings per share and revenue
On May 07, 2026, CAMP reported earnings of -0.32 USD per share (EPS) for Q1 26, missing the estimate of -0.21 USD, resulting in a -49.39% surprise. Revenue reached 1.29 million, compared to an expected 902.70 thousand, with a 43.35% difference. The market reacted with a +2.77% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.21 USD, with revenue projected to reach 1.24 million USD, implying an decrease of -34.38% EPS, and decrease of -3.83% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
What were CAMP4 Therapeutics Corporation Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, CAMP4 Therapeutics Corporation Common Stock reported EPS of -$0.32, missing estimates by -49.39%, and revenue of $1.29M, 43.35% above expectations.
How did the market react to CAMP4 Therapeutics Corporation Common Stock's Q1 2026 earnings?
The stock price moved up 2.77%, changed from $4.34 before the earnings release to $4.46 the day after.
When is CAMP4 Therapeutics Corporation Common Stock expected to report next?
The next earning report is scheduled for Aug 12, 2026.
What are the forecasts for CAMP4 Therapeutics Corporation Common Stock's next earnings report?
Based on --
analysts, CAMP4 Therapeutics Corporation Common Stock is expected to report EPS of -$0.21 and revenue of $1.24M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement